---
canonical_name: Tetradecylthioacetic Acid
alternate_names: TTA, Tetradecyl Thioacetic Acid, 2-(Tetradecylthio)acetic Acid, 3-Thia Fatty Acid
canonical_topic: Tetradecylthioacetic Acid for Health & Longevity
short_topic_lc: tetradecylthioacetic_acid
creation_date: 2026-0627-0130
creator_ai_fullname: Opus 4.8
---
# Tetradecylthioacetic Acid for Health & Longevity
Evidence Review created on 06/27/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 4.8
**Also known as:** TTA, Tetradecyl Thioacetic Acid, 2-(Tetradecylthio)acetic Acid, 3-Thia Fatty Acid
## Motivation
Tetradecylthioacetic acid (TTA) is a man-made fatty acid that looks almost identical to a normal dietary fat but carries one key change: a sulfur atom is placed near one end of its carbon chain. Because of that change the body cannot fully use TTA as fuel, so it lingers and acts as a long-lasting signal that nudges cells to burn more fat. This unusual behavior is what first made researchers curious about it.
TTA was first developed in Norway in the 1980s as a tool to study fat metabolism. In animals it lowers blood fats, trims body fat, calms inflammation, and behaves as an antioxidant, which sparked interest in it as a possible aid for heart and metabolic health. Human experience with it remains very limited, and it is sold in some places as an experimental supplement, though it has never been approved as a medicine.
This review examines what is known about TTA across laboratory, animal, and the limited human research, weighing its proposed benefits for fat metabolism and longevity against its risks, the gaps in human data, and the practical questions around its use.
**[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)**
## Recommended Reading
This section lists high-level, accessible overviews and key primary sources that introduce tetradecylthioacetic acid and its biology for a non-specialist reader.
* [Tetradecylthioacetic Acid Supplement, TTA Benefits, Dosage, Side Effects](https://www.genemedics.com/tetradecylthioacetic-acid) - Shanlikian
A clinician-authored consumer overview that summarizes TTA's proposed metabolic benefits, dosing, and reported side effects in plain language, making it a useful entry point before reading the primary literature.
* [Metabolic effects of thia fatty acids](https://pubmed.ncbi.nlm.nih.gov/12045400/) - Berge et al., 2002
A narrative review by the Bergen group that originated TTA, describing its core biology — mitochondrial proliferation, increased fat burning, anti-inflammatory and antioxidant actions — and why it shifts the blood-fat profile in a favorable direction. (Conflict of interest: this and most other TTA evidence comes from Rolf K. Berge's University of Bergen group, who developed and hold intellectual-property interests in the compound, so the originating party has a direct stake in favorable findings.)
* [Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation](https://pubmed.ncbi.nlm.nih.gov/19267708/) - Løvås et al., 2009
The published results of the small Phase 2 trial in men with type 2 diabetes — one of the very few human datasets on TTA — reporting its effects on blood fats and the proposed dual PPAR (peroxisome proliferator-activated receptor — a family of cellular switches for fat and energy metabolism) mechanism, making it essential reading for gauging how the rodent findings hold up in people.
* [Pharmacology and safety of tetradecylthioacetic acid (TTA): phase-1 study](https://pubmed.ncbi.nlm.nih.gov/18427285/) - Pettersen et al., 2008
The first-in-human safety and pharmacokinetic study in 18 healthy men, establishing that single daily doses up to 1000 mg for one week were well tolerated — the foundational human reference for anyone considering TTA.
* [The PPAR pan-agonist tetradecylthioacetic acid promotes redistribution of plasma cholesterol towards large HDL](https://pubmed.ncbi.nlm.nih.gov/32176696/) - Lundåsen et al., 2020
A more recent primary study detailing how TTA reshapes blood lipoproteins, shifting cholesterol toward larger HDL (high-density lipoprotein, "good cholesterol") particles, which illustrates the kind of mechanism-level effect that drives interest in the compound.
Note: No relevant content discussing TTA was found from any of the prioritized experts (Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser, Life Extension Magazine) despite both web and on-site searches; TTA is an obscure experimental compound not covered by mainstream longevity commentators. The list above therefore draws on a clinician-authored overview and key narrative/primary sources.
## Grokipedia
[Tetradecylthioacetic acid](https://grokipedia.com/page/tetradecylthioacetic_acid)
The Grokipedia article provides a structured technical overview of TTA's chemistry, molecular formula, and PPAR-related (peroxisome proliferator-activated receptor — a family of cellular switches for fat and energy metabolism) mechanisms, serving as a quick reference for its identity and basic pharmacology.
## Examine
[Tetradecyl Thioacetic Acid](https://examine.com/supplements/tetradecyl-thioacetic-acid/)
Examine's independent, evidence-graded page summarizes the human and animal research on TTA's benefits, dosage, and side effects, offering a balanced assessment of how weak the current human evidence base is.
## ConsumerLab
No ConsumerLab article exists for tetradecylthioacetic acid. ConsumerLab focuses on testing widely marketed consumer supplements, and TTA is an obscure experimental compound not covered by their product reviews.
## Systematic Reviews
No systematic reviews or meta-analyses for tetradecylthioacetic acid were found on PubMed as of 06/27/2026.
## Mechanism of Action
TTA is a synthetic 16-carbon saturated fatty acid in which a sulfur atom replaces a carbon at the 3-position (the "thia" substitution). Because of this sulfur atom, normal fat-burning machinery cannot fully break TTA down, so it accumulates and acts as a long-lived signaling molecule rather than a fuel.
Its central action is as a pan-agonist (broad activator) of the PPARs (peroxisome proliferator-activated receptors — a family of nuclear receptors that act as master switches for fat and energy metabolism), with a preference for PPAR-α (the subtype that drives fatty acid breakdown in the liver). Activating these receptors increases the production of enzymes that burn fatty acids and triggers mitochondrial biogenesis (the building of new mitochondria — the cell's energy-producing structures), raising the cell's overall capacity to oxidize fat.
The proposed downstream consequences include:
* **Fatty acid "drainage":** By boosting hepatic (liver) fat oxidation, TTA is hypothesized to pull fatty acids out of the blood and from fat stores, lowering blood triglycerides and improving insulin sensitivity.
* **Lipoprotein remodeling:** TTA lowers blood triglycerides and shifts cholesterol toward larger HDL particles, partly by reducing apolipoprotein C-III and increasing lipoprotein lipase activity (an enzyme that clears fat from blood).
* **Antioxidant and anti-inflammatory effects:** TTA can directly scavenge free radicals, inhibit oxidation of LDL (low-density lipoprotein, "bad cholesterol"), and reduce inflammatory signaling. Some of these effects appear in PPAR-α-knockout mice, indicating PPAR-independent mechanisms also contribute.
Competing mechanistic views exist: while the Bergen group frames TTA's benefits primarily through PPAR activation and mitochondrial fat oxidation, knockout-mouse data show that lipid-lowering and antioxidant effects persist without PPAR-α, suggesting that direct membrane and redox chemistry — not only receptor signaling — drive part of the response. The relative importance of these pathways in humans is unresolved. A structural caveat applies throughout this review: the great majority of the mechanistic, preclinical, and human evidence for TTA comes from the originating Bergen group (Berge and colleagues), who have a direct interest in the compound — so the body of evidence largely reflects a single source rather than broad, independent replication.
As a pharmacological compound, its key properties are: **half-life** — human pharmacokinetics show a roughly 1.5-hour lag, rapid absorption, and a slower elimination phase, with measurable accumulation over repeated daily dosing; **selectivity** — non-selective pan-PPAR agonist (α, δ/β, and γ) with preference for α; **tissue distribution** — concentrates in the liver and incorporates into cell membrane phospholipids across tissues; **metabolism** — resistant to complete β-oxidation due to the sulfur substitution, with partial chain-shortening and a characteristic Δ9-desaturated metabolite (TTA:1n-8) detected in plasma.
## Historical Context & Evolution
TTA was first synthesized and characterized in the 1980s by Rolf K. Berge and colleagues at the University of Bergen in Norway, originally as a research tool to probe how fatty acid structure controls fat metabolism. The "3-thia" design was intended to create a fatty acid that could enter metabolic pathways but resist being burned for energy, revealing how the cell handles such a molecule.
* **From research tool to candidate intervention:** As experiments accumulated, researchers observed that TTA did far more than serve as an inert probe — it actively lowered blood fats, reduced body fat, induced mitochondrial proliferation, and showed antioxidant and anti-inflammatory effects in rodents. These pleiotropic effects reframed TTA as a possible therapeutic for dyslipidemia (abnormal blood fats), metabolic syndrome, and cardiovascular disease, motivating its move toward health optimization.
* **Findings of the early research:** Rat and mouse studies repeatedly showed reductions in plasma triglycerides and cholesterol, increased fatty acid oxidation, megamitochondria formation in the heart, reduced arterial restenosis (re-narrowing of an artery after a procedure) after injury, and anti-tumor effects in several cancer cell models. A first-in-human Phase 1 study (2008) found the compound safe and well tolerated up to 1000 mg/day for a week, though it did not significantly move blood lipids over that short period.
* **Evolution of scientific opinion:** Initial enthusiasm framed TTA as a promising pan-PPAR agonist that could outperform single-target fibrate drugs. Subsequent knockout-mouse work complicated the simple "PPAR-α story" by showing PPAR-independent effects, and the broader pan-PPAR drug class drew caution after other pan/dual agonists (e.g., certain glitazars) failed in trials over safety concerns. TTA itself has not been disproven; rather, development stalled for lack of large, long-term human trials. What changed was not a verdict against TTA but the recognition that its human efficacy and long-term safety remain largely untested — the current standing is "mechanistically promising, clinically unproven" rather than settled in either direction.
## Expected Benefits
### Low 🟩
#### Triglyceride and Lipid Lowering
TTA consistently and substantially lowers plasma triglycerides and total cholesterol in rodents by activating PPAR-α and driving hepatic fatty acid oxidation, draining fat from the bloodstream. It also redistributes cholesterol toward larger, potentially more protective HDL particles and reduces apolipoprotein C-III. Human evidence is far weaker: the Phase 1 study in healthy men showed no significant short-term lipid change, and the small Phase 2 trial in type 2 diabetes was limited in size and duration, so the strong animal signal has not been confirmed in people.
**Magnitude:** In rodents, triglyceride reductions of roughly 30–70% are reported; in the brief human Phase 1 study no significant change was seen.
#### Improved Insulin Sensitivity & Anti-Adiposity
By increasing mitochondrial fat oxidation and reducing fat accumulation in liver and peripheral tissues, TTA improves insulin sensitivity and limits high-fat-diet-induced weight gain in animal models. The proposed mechanism is the "fatty acid drainage" effect, which lowers the lipid burden on muscle and liver that drives insulin resistance. These findings are robust across rodent studies but unconfirmed in adequately powered human trials.
**Magnitude:** Rodent studies show prevention of high-fat-diet-induced adiposity and measurable improvements in glucose handling; no quantified human effect-size is established.
#### Anti-Inflammatory & Antioxidant Effects
TTA reduces inflammatory signaling and oxidative stress, directly scavenging free radicals, inhibiting LDL oxidation, and lowering markers such as cyclooxygenase-2 (an enzyme driving inflammation) in animal models of hypertension and chronic inflammation. Some effects persist in PPAR-α-knockout mice, pointing to direct chemical antioxidant activity in addition to receptor signaling. Evidence is preclinical.
**Magnitude:** Not quantified in available studies.
### Speculative 🟨
#### Cardiovascular Protection
By combining triglyceride lowering, HDL remodeling, antioxidant action, anti-inflammatory effects, and reduced arterial restenosis after injury in animal models, TTA has been proposed as a broadly cardioprotective agent that shifts the blood profile "from atherogenic to cardioprotective." This integrated claim rests entirely on rodent and cell data plus mechanistic reasoning; no human cardiovascular outcome data exist.
#### Anti-Cancer / Anti-Proliferative Activity
TTA inhibits proliferation and induces cell death in several cancer cell lines (glioma, colon cancer, acute myelogenous leukemia) and slowed tumor growth in some animal models, possibly via PPAR-dependent and PPAR-independent endoplasmic-reticulum-stress pathways. This is early-stage laboratory work with no clinical evidence in cancer patients.
#### Mitochondrial Biogenesis & Longevity Support
TTA induces formation of new mitochondria and enhances cellular respiration, effects that overlap conceptually with pathways implicated in healthy aging (improved metabolic flexibility, reduced oxidative damage). The leap from mitochondrial biogenesis in rodent liver to human longevity is entirely speculative, supported only by mechanistic plausibility and indirect animal findings rather than any lifespan or healthspan data.
## Benefit-Modifying Factors
* **Genetic polymorphisms (PPAR variants):** Because TTA acts largely through PPARs, common variants such as PPARA and PPARG polymorphisms could plausibly alter responsiveness, as they do for fibrate and glitazone drugs. This has not been studied directly for TTA, so it remains a theoretical modifier inferred from the broader drug class.
* **Baseline biomarker levels:** Individuals with elevated baseline triglycerides, fatty liver, or insulin resistance would be expected to show larger relative benefits from a fat-oxidation-promoting agent, mirroring how lipid-lowering drugs work best in those with the most abnormal baseline values. Those with already-optimal lipids may see little change, as suggested by the null lipid result in healthy Phase 1 volunteers.
* **Sex-based differences:** Human data are essentially limited to male volunteers and male diabetic patients, so any benefit in women is unknown. PPAR-mediated lipid metabolism is known to differ by sex in animal models, making this an important unmeasured variable.
* **Pre-existing health conditions:** Metabolic conditions (type 2 diabetes, dyslipidemia, metabolic syndrome, fatty liver) are the contexts where benefit is most plausible, whereas in metabolically healthy individuals the benefit signal may be minimal.
* **Age-related considerations:** Mitochondrial function and metabolic flexibility decline with age, so older adults at the upper end of the target range might theoretically gain more from a mitochondrial-biogenesis-promoting compound; however, no age-stratified human data exist, and clearance and tolerability in older adults are uncharacterized.
## Potential Risks & Side Effects
### Low 🟥
#### Mild, Transient Adverse Events (Phase 1)
In the only dedicated human safety study, 18 healthy men taking up to 1000 mg/day for 7 days reported only a few adverse events of mild severity, with no clinically significant changes in blood counts, blood chemistry, or urine. This establishes short-term tolerability but says nothing about longer exposure. The nature of the mild events was non-specific and not clearly drug-attributable.
**Magnitude:** Few mild adverse events across 18 subjects over 7 days; no serious events reported.
#### Hepatic Lipid Accumulation
In animal studies, TTA can increase liver triglyceride content even while lowering blood triglycerides, because it shunts fatty acids into the liver for oxidation faster than they are fully consumed. In rodents fed a high-fat diet, liver fat rose despite plasma triglyceride falling. Whether this transient hepatic fat loading is harmful or benign in humans over the long term is unknown.
**Magnitude:** Not quantified in available studies.
### Speculative 🟨
#### Class-Related PPAR Agonist Risks
As a pan-PPAR agonist, TTA shares a receptor mechanism with drug classes (fibrates, glitazones, and experimental dual/pan "glitazars") that have been associated with fluid retention, weight gain, heart-failure risk, bone loss, and — for some pan agonists — concerns raised in animal carcinogenicity studies. None of these has been demonstrated for TTA specifically, but the shared mechanism makes them plausible and worth monitoring in any extended use.
#### Mitochondrial Proliferation / Peroxisome Effects
TTA induces marked mitochondrial proliferation and "megamitochondria" in rodent heart and liver. While interpreted as beneficial metabolic adaptation, extreme organelle proliferation and peroxisome proliferation in rodents have historically raised theoretical concerns about cellular stress and species-specific carcinogenic potential. The human relevance of rodent peroxisome-proliferation effects is debated and unproven for TTA.
#### Unknown Long-Term and Reproductive Safety
Because TTA accumulates rather than being burned and incorporates into cell membranes, and because no study has run beyond short durations, chronic-exposure effects, drug interactions, and reproductive or developmental safety are entirely uncharacterized. This absence of data is itself a meaningful risk for anyone using it as a long-term supplement.
## Risk-Modifying Factors
* **Genetic polymorphisms:** Variants in PPAR genes or in enzymes handling unusual fatty acids could in theory alter both efficacy and the likelihood of hepatic fat loading or other class effects; this is unstudied for TTA and inferred from the wider PPAR-agonist class.
* **Baseline biomarker levels:** Individuals with pre-existing elevated liver enzymes or fatty liver might be more vulnerable to the hepatic-lipid-accumulation effect seen in animals, making baseline liver assessment relevant before use.
* **Sex-based differences:** Human safety data come exclusively from men; sex differences in PPAR signaling and lipid handling mean the side-effect profile in women is unknown.
* **Pre-existing health conditions:** People with liver disease, heart failure, or a history of fluid retention could plausibly be more susceptible to class-related PPAR-agonist effects and to hepatic lipid loading, warranting greater caution.
* **Age-related considerations:** Older adults often have reduced hepatic and renal clearance and a higher baseline burden of cardiovascular and metabolic disease, which could amplify both unknown class risks and the consequences of any fluid retention; no age-specific safety data exist.
## Key Interactions & Contraindications
* **Lipid-lowering drugs (fibrates such as fenofibrate and gemfibrozil; statins):** Because TTA shares the PPAR-α mechanism of fibrates, combined use could have additive lipid-lowering and additive class-related effects. **Severity: caution.** **Consequence:** potential additive PPAR effects and theoretical increased risk of muscle or liver effects when stacked with statins. **Mitigating action:** avoid combining without medical monitoring of liver enzymes and creatine kinase.
* **Thiazolidinediones / glitazones (pioglitazone, rosiglitazone — PPAR-γ activators):** TTA also activates PPAR-γ, so co-use could produce additive fluid retention and weight-gain risk. **Severity: caution.** **Consequence:** edema, weight gain, possible heart-failure exacerbation. **Mitigating action:** avoid concurrent use, especially in those with cardiac risk.
* **Anticoagulants and antiplatelet agents (warfarin, aspirin, clopidogrel):** As a fatty-acid-like molecule with antioxidant/membrane effects, additive effects on platelet function cannot be excluded. **Severity: caution (theoretical).** **Consequence:** potential increased bleeding tendency. **Mitigating action:** monitor for bleeding; separate from invasive procedures.
* **Glucose-lowering drugs (insulin, sulfonylureas, metformin):** TTA's insulin-sensitizing action in animals could additively lower blood glucose. **Severity: monitor.** **Consequence:** hypoglycemia (low blood sugar) risk if combined. **Mitigating action:** monitor blood glucose and adjust diabetic medication under medical supervision.
* **Over-the-counter agents (high-dose niacin, omega-3 fish oil):** Both also lower triglycerides, giving additive lipid effects. **Severity: caution.** **Consequence:** additive triglyceride lowering, generally benign but unquantified. **Mitigating action:** be aware of cumulative effect.
* **Supplement interactions and additive supplements:** Other triglyceride- or inflammation-lowering supplements (omega-3 EPA/DHA, berberine, red yeast rice) would be expected to have additive metabolic effects with TTA; antioxidant supplements may overlap with its redox actions. **Severity: caution.** **Consequence:** additive but largely uncharacterized effects.
* **Populations who should avoid TTA:** Pregnant or breastfeeding women (no reproductive safety data); children and adolescents; people with active liver disease (e.g., Child-Pugh Class B or C); people with moderate-to-severe heart failure (NYHA, New York Heart Association, Class III–IV — a standard heart-failure severity scale) given class-related fluid-retention concerns; and anyone with a recent cardiovascular event, given the complete absence of human outcome data. **Severity for these groups: avoid / absolute contraindication for pregnancy.**
## Risk Mitigation Strategies
* **Baseline and follow-up liver monitoring:** Because animal data show hepatic lipid accumulation, check liver enzymes (ALT, AST) and ideally liver fat status before starting and re-check at roughly 4–8 weeks, to catch any rise early and mitigate the risk of unrecognized hepatic fat loading.
* **Conservative, low starting dose:** To limit exposure to an under-studied compound and reduce the chance of class-related effects, begin well below the 1000 mg/day Phase 1 ceiling (e.g., 200–600 mg/day) and only continue if tolerated, mirroring the dose tiers used in the human safety study.
* **Limit duration / avoid open-ended chronic use:** Since no human data extend beyond short durations, using TTA only in defined short courses rather than indefinitely mitigates the unknown long-term and accumulation risks inherent in a molecule that resists being burned off.
* **Monitor for fluid retention and weight gain:** Because pan-PPAR agonists as a class can cause edema and weight gain, track body weight and watch for ankle swelling, discontinuing if these appear, to mitigate the theoretical heart-failure-related risk.
* **Glucose monitoring when combined with diabetic therapy:** For anyone on insulin or other glucose-lowering drugs, self-monitor blood glucose to mitigate additive hypoglycemia risk from TTA's insulin-sensitizing effect.
* **Avoid in contraindicated populations:** Excluding pregnant/breastfeeding women, those with liver disease, and those with significant heart failure directly mitigates the highest-uncertainty safety risks given the absence of data in these groups.
## Therapeutic Protocol
TTA is an experimental compound with no approved clinical protocol; the parameters below reflect the doses used in the limited human research and by experimental-supplement users, not validated medical guidance.
* **Standard dose range (as studied):** The human Phase 1 study, conducted by the Bergen/Haukeland University Hospital group, used single daily oral doses of 200 mg, 600 mg, or 1000 mg for 7 days. Experimental-supplement sources commonly cite around 1000 mg (1 g) daily as a typical dose.
* **Leading practitioners / origin of the approach:** The dosing framework derives from Rolf K. Berge's group at the University of Bergen, who developed TTA and ran its human pharmacology studies; no integrative or clinical practice has established an independent protocol.
* **Competing approaches:** Because there is no established clinical use, the main "approaches" are simply the conservative low-dose tiers from the Phase 1 study versus the higher ~1 g/day used informally by supplement users. Neither is framed as standard, given the absent efficacy data.
* **Best time of day:** No circadian dosing data exist; sources suggest taking it with meals to aid absorption of a lipophilic (fat-soluble) compound, with no established advantage to morning versus evening dosing.
* **Expected half-life:** Human pharmacokinetics show a ~1.5-hour absorption lag, peak plasma levels at roughly 2.5–4.5 hours, and a slower elimination phase with measurable day-to-day accumulation; the compound is not rapidly cleared.
* **Single versus split dosing:** Because TTA is lipophilic and best absorbed with food, taking the daily amount in divided doses with meals is commonly suggested to improve tolerability and absorption, though single daily dosing was used in the formal study.
* **Genetic polymorphisms:** PPARA and PPARG variants could theoretically influence response and optimal dose, as they do for fibrates and glitazones, but no pharmacogenetic dosing guidance exists for TTA.
* **Sex-based differences:** All formal human dosing was in men; appropriate dosing in women is unknown.
* **Age-related considerations:** No age-adjusted dosing exists; older adults with reduced clearance may warrant lower, cautious dosing.
* **Baseline biomarker levels:** Those with higher baseline triglycerides may be the most likely to show a measurable response, making baseline lipid testing a sensible reference point for judging any effect.
* **Pre-existing health conditions:** Metabolic conditions are the plausible-use context, while liver disease and heart failure argue against use entirely.
## Discontinuation & Cycling
* **Lifelong versus short-term:** TTA is best regarded as a short-term, experimental compound rather than a lifelong intervention, because no human data support extended use and its resistance to being burned off raises accumulation concerns over time.
* **Withdrawal effects:** No withdrawal syndrome has been described; as a metabolic signaling fatty acid rather than a receptor agonist with rebound potential, abrupt stopping is not expected to cause acute withdrawal, though metabolic effects would be expected to fade as tissue levels decline.
* **Tapering protocol:** No tapering is documented or thought necessary; the compound can be stopped directly, after which plasma and tissue levels decline over its slower elimination phase.
* **Cycling:** Whether cycling preserves efficacy is unknown; given the unknown long-term safety, using defined short courses with breaks (a de facto cycling approach) is more about limiting cumulative exposure than maintaining a documented benefit.
* **Practical discontinuation note:** Because TTA incorporates into cell membranes and accumulates with daily dosing, users discontinuing after a longer course should expect a gradual rather than immediate offset of any effects.
## Sourcing and Quality
* **Regulatory and availability status:** TTA is not an approved drug and is sold only as an experimental research chemical or niche supplement by a small number of vendors; purity and labeling are not subject to medicine-grade oversight, so buyer caution is essential.
* **Third-party testing:** Because TTA is rarely tested by independent consumer-testing organizations (it is absent from ConsumerLab), buyers should seek vendors that provide a Certificate of Analysis (CoA) verifying identity and purity by HPLC (high-performance liquid chromatography, a lab technique that separates and measures a compound) or mass spectrometry, rather than relying on label claims alone.
* **Formulation considerations:** TTA is a lipophilic free fatty acid; look for clearly stated chemical identity (2-(tetradecylthio)acetic acid), purity percentage, and absence of solvent residues. Capsule formulations taken with food aid absorption.
* **Reputable sources:** No mainstream supplement brands or compounding pharmacies are established suppliers; the limited research supply has historically come from specialty chemical and research-supplement vendors, so verifying analytical documentation matters more here than brand recognition.
* **What to look for overall:** Prioritize a documented CoA, transparent sourcing, accurate chemical naming, and realistic claims; treat any vendor making strong human-efficacy or longevity claims as a red flag given the absence of supporting human evidence.
## Practical Considerations
* **Time to effect:** In animals, metabolic effects on blood fats develop over days to weeks of daily dosing; in the brief human study no significant lipid change occurred within a week, so any human benefit (if real) would likely require sustained dosing over weeks, with no reliable timeline established.
* **Common pitfalls:** Over-relying on dramatic rodent results and assuming they translate to humans; using high doses for long periods despite the absence of long-term safety data; taking it on an empty stomach (reducing absorption of a fat-soluble compound); and buying from vendors without analytical verification.
* **Regulatory status:** TTA has no FDA approval for any indication and is not a recognized dietary ingredient; its sale and use fall into an experimental/grey-market category, and any use is effectively off-label and unsupervised.
* **Cost and accessibility:** TTA is relatively difficult to obtain, available mainly from niche research-supplement vendors rather than mainstream retailers, and can be comparatively expensive for a non-approved compound with uncertain benefit.
* **Realistic expectations:** Given that the strongest evidence is preclinical and the single human safety study showed no significant lipid effect, users should regard TTA as experimental with unproven human benefit rather than a validated metabolic or longevity aid.
## Interaction with Foundational Habits
* **Sleep:** The interaction is **indirect** and not directly studied. By improving mitochondrial function and metabolic flexibility in theory, TTA could indirectly support energy metabolism, but there is no evidence it improves or disrupts sleep, and no mechanism suggesting a direct effect on sleep architecture. No timing considerations relative to sleep are established.
* **Nutrition:** The interaction is **direct and potentiating** in the sense that TTA is a fat-soluble compound best absorbed with dietary fat, so taking it with meals enhances uptake. Its fat-oxidation-promoting mechanism overlaps with the goals of carbohydrate-restricted or calorie-controlled diets, and it is most likely relevant against a background of a high-fat or metabolically challenged diet, mirroring the high-fat-diet rodent models. No specific nutrient depletion is documented.
* **Exercise:** The interaction is **potentiating in theory** and **none demonstrated in practice.** Both exercise and TTA promote mitochondrial biogenesis and fat oxidation, so the mechanisms converge and could be additive, but there are no human studies on whether TTA enhances or blunts training adaptations. No evidence suggests it impairs hypertrophy, and no workout-timing guidance is established.
* **Stress management:** The interaction is **indirect and largely none.** TTA's anti-inflammatory and antioxidant actions could in principle reduce oxidative stress at the cellular level, but there is no evidence it affects the cortisol/psychological stress response, and no practical stress-management considerations are established.
## Monitoring Protocol & Defining Success
Because TTA is experimental and primarily affects lipid and metabolic parameters, baseline testing focuses on lipids, liver health, and glucose, with follow-up to detect both efficacy signals and the hepatic-lipid risk seen in animals. Baseline labs should be drawn before starting to establish reference values for each individual.
Ongoing monitoring is reasonable at roughly 4–8 weeks after starting, and then every 3–6 months if use continues, with particular attention to liver enzymes given the animal data on hepatic fat accumulation.
| Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes |
|---|---|---|---|
| Triglycerides | < 80 mg/dL | Primary expected target of TTA | Fasting 9–12 h; conventional cutoff is < 150 mg/dL, functional target is lower |
| Total / HDL / LDL cholesterol | HDL > 50 mg/dL (women) / > 40 (men); LDL context-dependent | Tracks lipoprotein remodeling toward larger HDL | Fasting lipid panel; best paired with triglycerides |
| ALT / AST (liver enzymes) | ALT < 25 U/L; AST < 25 U/L | Detects hepatic stress / lipid accumulation risk | Conventional upper limits (~40 U/L) are higher than functional targets; recheck early |
| Fasting glucose | 70–85 mg/dL | Detects insulin-sensitizing effect and hypoglycemia risk | Fasting; pair with HbA1c |
| HbA1c | < 5.4% | Longer-term glucose control if used for metabolic goals | HbA1c (glycated hemoglobin, a marker of average blood sugar) is not fasting-dependent; reflects ~3-month average |
| Fasting insulin / HOMA-IR | Insulin < 6 µIU/mL; HOMA-IR < 1.5 | Assesses insulin sensitivity, the main animal benefit | HOMA-IR (a calculated index of insulin resistance) requires fasting; functional ranges tighter than lab "normal" |
| hs-CRP | < 1.0 mg/L | Tracks anti-inflammatory effect | hs-CRP (high-sensitivity C-reactive protein, a marker of low-grade inflammation); avoid testing during acute illness; fasting not required |
Qualitative markers to track alongside labs:
* Energy levels and perceived metabolic "flexibility" during fasting or exercise
* Body weight and waist circumference trends
* Any ankle swelling or unexplained rapid weight gain (possible fluid retention — a reason to stop)
* General tolerability (digestive comfort when taken with meals)
## Emerging Research
* **No ongoing clinical trials:** A ClinicalTrials.gov search as of 06/27/2026 found no active, recruiting, or planned interventional trials of TTA the compound; the only registered TTA-compound study is the completed Phase 2 trial below, so there is currently no ongoing human pipeline.
* **Completed Phase 2 trial in diabetes and dyslipidemia:** A small Phase 2 study, [NCT00605787](https://clinicaltrials.gov/study/NCT00605787) (Haukeland University Hospital, completed, 16 male participants with type 2 diabetes and dyslipidemia, primary endpoint plasma lipids), tested short-term effects of TTA on blood fats and glucose. Its small size limits conclusions and illustrates how thin the human trial base remains.
* **Foundational human safety data:** The Phase 1 randomized study, [Pettersen et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18427285/), remains the key human reference establishing short-term tolerability up to 1000 mg/day; future trials could either confirm or challenge whether this safety holds over longer exposure.
* **Lipoprotein-remodeling mechanism (strengthening direction):** Recent mechanistic work such as [Lundåsen et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32176696/) details how TTA shifts cholesterol toward larger HDL particles, a direction of research that could strengthen the cardiovascular rationale if replicated in humans.
* **Mitochondrial biogenesis and mTOR signaling:** Work showing TTA induces mitochondrial biogenesis with mTOR (mechanistic target of rapamycin — a master regulator of cell growth and metabolism) regulation in hepatocytes, [Hagland et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23228666/), points to longevity-relevant pathways but also raises questions (e.g., signaling crosstalk) that future studies could resolve in either direction.
* **PPAR-independent and class-risk questions (weakening direction):** Findings that key effects persist in PPAR-α-knockout models, together with the broader safety setbacks of pan/dual PPAR agonists as a drug class, define a research direction that could weaken the case for TTA if long-term studies surface class-related harms; targeted long-duration safety and carcinogenicity studies are the most important open area.
* **Future research areas:** The decisive open questions are whether TTA's striking rodent metabolic benefits translate to humans in adequately powered, longer trials, and whether chronic accumulation of a non-oxidizable fatty acid carries any cumulative toxicity — neither of which current data can answer.
## Conclusion
Tetradecylthioacetic acid is a laboratory-made fat-like molecule, designed with a sulfur atom that stops the body from burning it, so it instead acts as a long-lasting signal that switches on the cell's fat-burning and energy-building machinery. In animals it lowers blood fats, trims body fat, calms inflammation, works as an antioxidant, and builds new energy-producing structures inside cells, which is why it has drawn interest as a possible aid for heart and metabolic health and, more speculatively, for healthy aging.
The gap between this promise and proof is wide. Almost all the encouraging findings come from cell and rodent studies. Human testing is limited to a small short-term safety study, where it was well tolerated but did not clearly change blood fats, and one small trial in people with diabetes. The available human evidence covers only short-term use in men, and as a broad metabolic switch TTA may carry risks seen with similar compounds, including liver fat buildup and fluid retention. Weighing the evidence is further complicated by the fact that almost all of it comes from the single research group that created the compound, which has a direct stake in its favorable reception.
The honest summary is that TTA is mechanistically interesting but clinically unproven. It remains an experimental compound with genuine biological activity, while its benefits in people and its long-term safety stay unconfirmed.
**[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**